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The presynaptic protein a-synuclein is a prime suspect for con-
tributing to Lewy pathology and clinical aspects of diseases,
including Parkinson’s disease, dementia with Lewy bodies, and a
Lewy body variant of Alzheimer’s disease. a-Synuclein accumu-
lates in Lewy bodies and Lewy neurites, and two missense
mutations (A53T and A30P) in the a-synuclein gene are geneti-
cally linked to rare familial forms of Parkinson’s disease. Under
control of mouse Thy1 regulatory sequences, expression of A53T
mutant human a-synuclein in the nervous system of transgenic
mice generated animals with neuronal a-synucleinopathy, fea-
tures strikingly similar to those observed in human brains with
Lewy pathology, neuronal degeneration, and motor defects, de-
spite a lack of transgene expression in dopaminergic neurons of
the substantia nigra pars compacta. Neurons in brainstem and
motor neurons appeared particularly vulnerable. Motor neuron
pathology included axonal damage and denervation of neuro-
muscular junctions in several muscles examined, suggesting that
a-synuclein interfered with a universal mechanism of synapse
maintenance. Thy1 transgene expression of wild-type human
a-synuclein resulted in similar pathological changes, thus support-
ing a central role for mutant and wild-type a-synuclein in familial and
idiotypic forms of diseases with neuronal a-synucleinopathy and
Lewy pathology. These mouse models provide a means to address
fundamental aspects of a-synucleinopathy and test therapeutic
strategies.
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Idiopathic Parkinson’s disease (PD), dementia with Lewy bodies
(DLB), and a Lewy body variant of Alzheimer’s disease (LBVAD)
are characterized pathologically by proteinaceous inclusions in
neurons commonly referred to as Lewy pathology in postmortem
brain tissue samples (Forno, 1996; Ince et al., 1998; Irizarry et al.,
1998; Spillantini et al., 1998; Takeda et al., 1998; Braak et al., 1999).
The inclusions occur in the dystrophic (Lewy) neurites that con-
stitute an important part of the pathology of PD and DLB (Irizarry
et al., 1998; Spillantini et al., 1998; Braak et al., 1999), in neuronal
perikarya (Lewy bodies) (Forno, 1996; Spillantini et al., 1997; Wak-
abayashi et al., 1997; Baba et al., 1998; Ince et al., 1998; Irizarry et al.,
1998; Mezey et al., 1998; Spillantini et al., 1998; Takeda et al., 1998;
Braak et al., 1999), and occasionally extracellularly (Den Hartog and
Bethlem, 1960).
a-Synuclein is the major constituent of Lewy bodies and Lewy
neurites (Spillantini et al., 1997; Wakabayashi et al., 1997; Baba et
al., 1998; Ince et al., 1998; Irizarry et al., 1998; Mezey et al., 1998;
Spillantini et al., 1998; Takeda et al., 1998; Arai et al., 1999; Braak
et al., 1999; Giasson et al., 2000). To lesser and varying degrees,
these inclusions contain ubiquitin (Gai et al., 1995), neurofilament
proteins (Forno, 1996; Ince et al., 1998; Takeda et al., 1998),
ubiquitin C-terminal hydrolase (Lowe et al., 1990), proteosomal
subunits (Li et al., 1997), and a variety of other antigenic determi-
nants (Pollanen et al., 1993). a-Synuclein immunoreactivity is the
most sensitive and reliable diagnostic for Lewy-type pathology
(Forno, 1996; Spillantini et al., 1997; Wakabayashi et al., 1997;
Baba et al., 1998; Ince et al., 1998; Irizarry et al., 1998; Mezey et al.,
1998; Spillantini et al., 1998; Takeda et al., 1998; Braak et al., 1999).
Lewy pathology in neurons appears to be central and may
contribute mechanistically to their dysfunction and degeneration in
disease. Altogether, the distribution of a-synuclein-containing in-
clusions in disorders with Lewy pathology, the discovery of two
mutations in the a-synuclein gene linked to early-onset familial PD
(Polymeropoulos et al., 1997; Kru¨ger et al., 1998), the ability of the
protein to self-aggregate (Conway et al., 1998, 2000; Giasson et al.,
1999; Narhi et al., 1999; Wood et al., 1999), and recent findings
in vivo in transgenic flies (Feany and Bender, 2000) and mice
(Masliah et al., 2000) are supporting a central role for a-synuclein
in the pathophysiology of diseases with Lewy pathology.
Here, we demonstrate pathology with neuronal degeneration
and accompanying motor deficits in mice, by neuronal expression
of the A53T mutant of human a-synuclein or its wild-type coun-
terpart. a-Synuclein-encoding cDNAs were under control of mouse
Thy1 regulatory sequences (Lu¨thi et al., 1997; Sturchler-Pierrat et
al., 1997; Wiessner et al., 1999) that produced reliably neuron-
specific expression and high protein levels in many central neurons
of the mouse nervous system.
MATERIALS AND METHODS
Transgenic mice. Wild-type human a-synuclein cDNA (396 bp) was PCR
amplified (2 min, 93°C; three cycles of 15 sec, 93°C; 30 sec, 55°C; 30 sec,
72°C; two cycles of 15 sec, 93°C; 30 sec, 60°C; 30 sec, 72°C; and 30 cycles
of 15 sec, 93°C; 30 sec, 66°C; 30 sec, 72°C; oligonucleotides, cgacgacagtgt-
ggtgtaaaggaa and tgggcacattggaactgagcactt) from 20 ng of human brain
cDNA (Clontech, Palo Alto, CA) and cloned into pMOSBlue (Amersham
Pharmacia Biotech, Little Chalfont, UK). The A53T mutation was intro-
duced using PCR oligonucleotide-directed mutagenesis (Stratagene, La
Jolla, CA; 30 sec, 93°C; 14 cycles of 30 sec, 93°C; 1 min, 55°C; 13 min, 68°C;
oligonucleotides, agtggtgcatggtgtgacaacagtggctgaga and tctcagccactgttgt-
cacaccatgcaccact). The identity of wild-type and mutant cDNA was con-
firmed by sequencing and the corresponding blunted (Klenow) cDNAs
(NdeI-SmaI) inserted into the blunted (XhoI site) Thy1 cassette (Lu¨thi et
al., 1997; Sturchler-Pierrat et al., 1997; Wiessner et al., 1999). For micro-
injection, linear NotI DNA fragments comprising transgene without plas-
mid vector sequences were isolated. Injection was into homozygous
C57BL/6 mouse eggs. Genotyping was performed by PCR (oligonucleo-
tides were identical to those used for cloning the human a-synuclein
cDNA; 5 min, 95°C; 30 cycles of 30 sec, 95°C; 1 min, 60°C; 1 min, 72°C; 10
min, 72°C) using column-purified (Qiagen, Hilden, Germany) tail DNA.
Northern blot analysis. Northern blot analysis was performed with total
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brain RNA (TriZol method; 10 mg loaded per gel lane). Probes were either
364 (Fig. 1 A, probe A) or 111 bp of the human a-synuclein cDNA (Fig. 1 A,
probe B; unlike probe A, probe B lacks homology to cDNAs encoding
a-synuclein-related family members) (Lavedan, 1998), or 600 bp of mouse
Thy1 39 untranslated sequences (Lu¨thi et al., 1997) (Fig. 1 A, probe C).
Standard procedures were used.
Immunoblot analysis. For Western blot analysis, 14,000 3 g supernatant
fractions were used of half-brain homogenates [homogenized in 2 ml of
E-buffer (50 mM Tris-HCl, pH7.4, 1% NP-40, 0.25% Na-deoxycholate, 150
mM NaCl, 1 mM EDTA, and a cocktail of protease inhibitors (Boehringer
Mannheim, Mannheim, Germany) and left on ice for 30 min]. Fifteen, 25,
or 50 mg of protein was loaded per lane and separated on 15% SDS-PAGE.
After blotting and blocking nonspecific binding, membranes were incu-
bated with rabbit anti-a-synuclein polyclonal antibody (1:1000; AB5038;
Chemicon, Temecula, CA), followed by alkaline phosphatase (AP)-conjugated
anti-rabbit IgG (1:50,0000; AO418; Sigma, St. Louis, MO), or the anti-
human-a-synuclein-specific antibody LB509 (1:5000; Zymed, San Fran-
cisco, CA), followed by AP-conjugated anti-mouse IgG1 (1:40,000; Sigma)
and chemiluminescent detection (Clontech).
In situ hybridizations. The spatial distribution pattern of transgene versus
endogenous a-synuclein expression was determined by in situ hybridiza-
tion (Wiessner et al., 1999). cRNA was transcribed using T7-RNA poly-
merase and a 364 bp cDNA template (complete human a-synuclein coding
region) or a 111 bp cDNA template (corresponding to the region encoding
amino acids 103–140 of human a-synuclein).
Immunocytochemistry. Mice (aged 3.8–6 months) were injected with
pentobarbital (50 mg/ml Nembutal; Abbott laboratories, North Chicago,
IL) and perfused transcardially with 0.01 M PBS, followed by 4% parafor-
maldehyde in PBS. One brain hemisphere, spinal cord, and hind limb
muscle were embedded in paraffin and cut as 4-mm-thick sections. Vi-
bratome sections (25 mm) were cut from the other hemisphere for free-
floating immunocytochemical staining using anti-a-synuclein mouse
monoclonal antibody (1:500; S63320; Transduction Laboratories, Lexing-
ton, KY), biotinylated anti-mouse IgG (1:500; E0464; Dako, Copenhagen,
Denmark), and the avidin-biotin peroxidase method (Elite standard kit
SK6100; Vector Laboratories, Burlingame, CA). In addition, the following
antibodies were used: AT8 monoclonal, which detects paired helical fila-
ment and hyperphosphorylated tau (1:1000; BR-003; Innogenetics, Zwijn-
drecht, Belgium); neurofilament 200 kDa-specific monoclonal, detecting
normal and phosphorylated neurofilaments (1:100; NCL-NF200; Novocas-
tra, Newcastle, UK); neurofilament M and H monoclonal (phophorylated
forms; 1:500; MAB 1592; Chemicon). Stainings (including also Congo red
and thioflavine S) were as described by Sturchler-Pierrat et al. (1997).
Deparaffinized sections were used for Campbell–Switzer silver staining
(Campbell et al., 1987), Holmes–Luxol staining (Holmes, 1943), and
immunostaining with rabbit anti-ubiquitin Ig fraction (1:200; Z0458;
Dako), rabbit anti-glial fibrillary acidic protein (GFAP) Ig fraction (1:500;
Z0334; Dako), anti-phosphotyrosine mouse monoclonal antibody (1:1500;
P3300; Sigma), and anti-human a-synuclein-specific mouse monoclonal
antibody (LB509; 1:2000; 18–0215; Zymed) (Baba et al., 1998; Jakes et al.,
1999). Antigenity was enhanced by treating paraffin sections with concen-
trated formic acid for 5 min and microwave heating at 90°C for 60 min
before incubation with anti-a-synuclein, microwave heating at 90°C for 30
min before anti-GFAP and anti-phosphotyrosine, and pronase treatment
(37°C, 30 min) before anti-ubiquitin. Nonspecific binding sites were
blocked using normal serum. Bound antibody was visualized using the
avidin-biotin peroxidase method (Elite standard kit SK6100; Vector Lab-
oratories) and DAB substrate (1718096; Boehringer Mannheim) or Vector
Laboratories AEC substrate (SK-4200). Immunostaining and confocal
analysis of neurofilament and synaptophysin at neuromuscular junctions
(NMJs) were as follows. Mice were killed by anesthesia. Extensor digito-
rum longus (EDL) and soleus muscles were excised and stained with Alexa
Fluor 488-labeled a-bungarotoxin (1:1000 in F-15 medium; Molecular
Probes, Eugene, OR) for 2 hr at 4°C, followed by several rinses with PBS.
Muscles then fixed with cold methanol (220°C) and permeabilized with
blocking solution (PBS containing 5% horse serum, 1% BSA, 1% Triton
X-100, and 0.1% sodium azide) for 2 hr at 4°C. Tissue was subsequently
incubated with primary antibodies against either neurofilament (1:500 in
blocking solution; Sigma) or synaptophysin (1:200 in blocking solution;
Dako) and was incubated for 40 hr at 4°C. After several rinses with PBS,
muscles were incubated with Cy3-labeled goat anti-rabbit IgG (1:1000 in
blocking solution; Jackson ImmunoResearch, West Grove, PA) overnight
at 4°C. The muscles were thoroughly rinsed with PBS and mounted on
glass slides using Citifluor (Plano). The tissue was examined with a
confocal microscope (model TCS NT; Leica, Nussloch, Germany).
Immunoelectron and electron microscopy. For immunoelectron micros-
copy, transgenic and wild-type C57BL/6 mice were perfused transcardially
with a mixture of 1.5% picric acid, 0.1% glutaraldehyde, and 4% parafor-
maldehyde in 0.1 M phosphate buffer, pH 7.4. Vibratome sections were
stained free-floating with antibody to a-synuclein (LB509; 1:2000) dehy-
drated in ascending series of ethanol and acetone, and flat-embedded
between glass slide and coverslips in Embed-812 (Electron Microscopy
Sciences, Fort Washington, PA). Fragments of the spinal cord were then
dissected out and ultrathin sections were cut from the tissue surface, and
these were mounted on copper grids and analyzed with a Zeiss
(Oberkochen, Germany) EM900 microscope. For conventional electron
microscopy, mice were anesthetized and perfused transcardially with cold
saline, followed by 4% paraformaldehyde and 0.1% glutaraldehyde in 0.1 M
cacodylate buffer. Small tissue blocks were cut out from brainstem and
spinal cord, immersion-fixed for 12 hr at 4°C in the same buffer, and
epoxy-embedded, and ultrathin sections were prepared and placed on
200-mesh copper grids for staining with uranyl acetate and lead citrate.
Silver-esterase staining of neuromuscular junctions. The combined silver-
esterase technique was applied on gastrocnemius muscle. This muscle was
freshly dissected and, after a brief wash in 10 mM EDTA in PBS, the tissue
was mounted for cryostat sectioning and cut (50 mm longitudinal sections).
Slides were rinsed in 80 mM EDTA in PBS before mounting sections.
Sections were dried for 30–120 min at 37°C, immersed in sodium sulfate
(29%) for 3 min, washed in H2O, and incubated for 25 min at 37°C in
acetylcholinesterase staining solution (Pestronk and Drachman, 1978).
After washing in H2O, sections were dehydrated in 70 and 100% ethanol,
respectively, for 1–2 min each. Next, sections were fixed in buffered formol
Figure 1. Transgene expression. A, Schematic representation of the trans-
gene. Roman numerals refer to exons in the endogenous murine Thy1 gene.
Boxes represent a complete a-synuclein coding cDNA probe (A), a C-terminal
111 bp a-synuclein cDNA probe (B), and a Thy1 39 untranslated region
probe (C) (Lu¨thi et al., 1997). Arrows represent PCR primers for genotyp-
ing. B, Northern blot analysis of 10 mg of total brain RNA using probe A
and brain RNA of a C57BL/6 nontransgenic mouse (lane 1), a line 9813
mouse (lane 2), a line 9956 mouse (lane 3), and the single transgenic male
of line 9832 (lane 4 ). The arrowhead refers to the transgene mRNA, and the
horizontal bar marks the position of endogenous mouse a-synuclein mRNA.
C, Immunoblot analysis showing increased levels of a-synuclein protein in
brain homogenates of a representative mouse of each of the lines 9956 (lane
1), 9813 (lane 2), the single F1 male of line 9832 (lane 3), and C57BL/6 (lane
4 ). The polyclonal rabbit antibody used (Chemicon) detects both mouse
and human a-synuclein protein. D, Immunoblot using the antibody LB509
(specifically detects human but not the mouse a-synuclein protein; Zymed)
and line 9956 (lane 1), line 9813 (lane 2), and C57BL/6 (lane 3). E, F, In situ
hybridization in sagittal brain sections of a line 9813 mouse (E) and a
C57BL/6 mouse (F) using 35S-labeled cRNA corresponding to probe A (A).
G, H, In situ hybridization in horizontal brain sections of a line 9813 mouse
(G) and a C57BL/6 mouse (H ) using 35S-labeled cRNA corresponding to
probe B (A).
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saline (Pestronk and Drachman, 1978) for 30 min at room temperature,
washed in H2O, and pretreated for 30 min at 37°C in 10% chloral hydrate
(w/v) containing 1% pyridine (v/v). After washing in H2O, the sections
were incubated in a freshly prepared solution of 20% silver nitrate con-
taining 1% cupric sulfate. Calcium carbonate was added to each slide
separately. Incubation was for 40 min at 37° before discarding the solution,
washing in H2O, and incubation for 10 sec and 3–5 min, respectively, in a
bath of 1% hydroquinone and 5% sodium sulfite. After washing in H2O,
sections were fixed (2–5 min) in 5% sodium thiosulfate, washed (in H2O),
toned for 5 min in 0.2% sodium tetrachloroaureate (after adding freshly a
drop of glacial acetic acid), washed (in H2O), immersed in 1% oxalic acid
for 20–120 sec, washed (in H2O), fixed again in 5% sodium thiosulfate,
washed (in H2O), dehydrated in ethanol, air dried, rinsed in xylene, air
dried, and mounted.
Rotating rod. The mice were trained twice daily and on two successive
days to stay on a rotating rod (Technical and Scientific Equipment, Bad
Homburg, Germany) for 150 sec (speed of 12 rpm). Subsequently, the
animals were tested on the rotating rod once weekly, three times and at
three different speeds (i.e., 12, 24, and 36 rpm). The cutoff time used for
measuring the endurance performance in all of these experiments was 60
sec. The plotted mean endurance performance on a particular test day was
the mean of the three performances at the given speed. Statistical evalu-
ation of the data were using repeated measures ANOVA.
RESULTS
Six transgenic C57BL/6 lines were produced, each expressing a
Thy1aSNA53T transgene to a different level. The two lines de-
scribed in this report (9813 and 9956) expressed transgene mRNA
levels (Fig. 1B, mRNA levels were 9832 . 9813 . 9956 as shown
for three lines; others not shown) that each resulted in increased
levels of a-synuclein protein in brain (Fig. 1C, antibody cross-
reacting with mouse and human a-synuclein; Fig. 1D, antibody
detecting only human a-synuclein). In both lines, transgene expres-
sion occurred in neurons throughout the telencephalon, brainstem,
and spinal cord, as shown in a representative sagittal section of a
mouse brain of line 9813 (Fig. 1E). In situ hybridization with a
cRNA probe that corresponds to the full-length coding sequence of
human a-synuclein (Fig. 1A, probe A), shows the transgene mRNA
expression pattern superimposed on that of endogenous mouse
a-synuclein, the latter being apparent mainly in the telencephalon
(Fig. 1F). Transgene expression pattern was also monitored spe-
cifically using a cRNA probe that corresponds to 111 bp encoding
the C-terminal 37 amino acids of human a-synuclein (Fig. 1A,
probe B). This probe is 87.5% homologous to mouse cDNA but has
nucleotide differences occurring every 10–20 bp. As a result and as
shown in a pair of horizontal sections, this probe detects no signal
above background (as verified also by Northern blot analysis; data
not shown) in the nontransgenic C57BL/6 mouse brain (Fig. 1H),
whereas the signal in the transgenic brain reflects specifically the
transgene expression pattern (Fig. 1G).
In all of the mice of lines 9813 and 9956, we observed an
early-onset (.3 weeks of age) and a progressive decline of motor
performance. A more severe motor deficit was seen in a single
transgenic F1 male of a third independent founder (line 9832). This
male died at an age of 5 weeks and the line was lost. Brain
transgene mRNA levels in the line 9832 single F1 male (Fig. 1B,
lane 4) superseded those detected in line 9813.
The progressive decline in motor performance was measured in
a rotating rod experiment. A group of transgenic (n 5 7) versus
nontransgenic (n 5 12) littermate males of line 9813 were com-
pared, starting at age 40 d and up to age 200 d (Fig. 2). The results
show a progressive decline in motor performance and a dramatic
reduction in endurance of the transgenic mice to remain on the
rotating rod. A similar difference and effect was observed when
comparing aging (40–200 d) female transgenic (n 5 15) versus
nontransgenic (n 5 8; data not shown) mice of line 9813. The
ANOVA indicated a highly significant effect of genotype ( p ,
0.001), as well as a significant age, speed, and genotype interaction
( p , 0.005; repeated measures ANOVA for two trial factors).
A comparison of the performance curves of the two groups (trans-
genic and wild-type) revealed that, at both speeds 12 and 36 rpm,
the performance of the transgenic animals differed significantly
( p , 0.001) from that of their nontransgenic littermates.
The pronounced motor phenotype found in all of the mice of
both A53T transgenic lines and the documented expression of
Thy1-based transgenes in motor neurons (Aigner et al., 1995)
prompted us to examine more closely the pathological changes in
these cells. In the anterior horns of the spinal cord, ;80% of the
motor neurons expressed the human a-synuclein A53T mutant
protein, as shown by immunoreactivity for the human a-synuclein-
specific antibody LB509 (Baba et al., 1998; Jakes et al., 1999).
Specific to the transgenic mice, many of these cells showed diffuse
perikaryal a-synuclein staining (Fig. 3A) and some also showed
Lewy-like pathology (Fig. 3C, D) with pronounced ubiquitin im-
munoreactivity (Fig. 3D). Furthermore, staining with the Camp-
bell–Switzer pyridine silver technique (Campbell et al., 1987) (Fig.
3C), a routine and sensitive method used to detect Lewy-type
changes in human brain tissue (Braak and Braak, 1999; Sandmann-
Keil et al., 1999), revealed intense staining. These results indicate
that (rodent) motor neurons are susceptible to Lewy-like changes
when expressing the A53T mutant of human a-synuclein. Other
changes associated with the development of the motor neuron
pathology (and seen also in other affected brain regions; data not
shown) included astrocytic gliosis (Fig. 3E) and microglial activa-
tion (Fig. 3F).
Spinal roots (Fig. 4A) and nerve fiber bundles in muscles (Fig.
4C) immunostained for a-synuclein. Axonal degeneration was ap-
parent in spinal roots, with nerve fibers showing breakdown and
segmentation into ellipsoids of the myelin sheath (Fig. 4B). Also,
skeletal muscles contained small angular fibers (Fig. 4D, arrow-
heads), indicating neurogenic muscular atrophy, consistent with the
denervation and neuropathology observed to varying degrees at
NMJs of gastrocnemius muscle taken from several line 9813 mice
(n 5 7, age 6.5 months; Fig. 4E–J). Depending on the individual
mouse, 10–40% of the synapses were denervated and thinning of
preterminal nerves, and/or swellings were detected in at least 50%
of innervated synapses. Pathological changes were also observed in
two other muscles, the EDL, containing fast-twitch muscle fibers,
and the soleus, which contains mostly slow-twitch muscle fibers
(Fig. 5). Whereas the structure of the postsynaptic apparatus,
visualized by a-bungarotoxin, was similar in transgenic and wild-
type mice, the presynaptic motor neurons showed clear signs of
degeneration. In transgenic but not in wild-type C57BL/6 litter-
mates, NMJs often showed a reduction in the neurofilament stain-
ing, indicating that motor neurons were about to retract from
synapses (Fig. 5C, D). Moreover, neurofilament staining in more
proximal regions of the motor nerve was discontinuous (data not
shown). The hypothesis that motor neurons abandon synaptic sites
was supported in staining for the synaptic vesicle protein synapto-
physin (Fig. 5A, B). In wild-type animals, synaptophysin matches
the outline of the postsynaptic acetylcholine receptors (AChRs)
(Fig. 5A). In transgenic animals, synaptophysin appeared punctated
Figure 2. Rotating rod performance of transgenic mice. Starting at age
40 d and up to age 200 d, transgenic (n 5 7) and C57BL/6 nontransgenic
(n 5 12) littermate male mice were tested for endurance to stay on the
rotating rod. The mice were tested weekly, and their performance is shown
for two different rotation speeds, speed 1 (12 rpm) and speed 3 (36 rpm).
C57BL/6 mice showed maximum endurance performance (60 sec) at both
speeds and as shown for speed 3 (36 rpm).
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and thinner so that it did not cover the entire area of AChR
aggregates (Fig. 5B). The finding that neurodegeneration including
denervation of NMJs is observed in all of the muscles examined
suggests that a universal mechanism of synapse maintenance is
affected by transgene expression of human a-synuclein. Together
with the neuropathological changes detected in central areas (see
below), including some that are involved in motor function (e.g.,
globus pallidus; data not shown), these findings provide a likely
explanation for the observed reduction in complex motor
performance.
To investigate pathological changes in the brain more closely,
animals of both lines, aged 12 weeks and older (n 5 19), were
examined by applying immunohistochemical techniques routinely
used to assess Lewy pathology in human brain (Gai et al., 1995;
Forno, 1996; Spillantini et al., 1997; Wakabayashi et al., 1997; Baba
et al., 1998; Ince et al., 1998; Mezey et al., 1998; Takeda et al.,
1998). In transgenic mouse brains, many neurons in the telenceph-
alon (Fig. 6A,B,D,E) and brainstem (Fig. 7B,C) showed intense
a-synuclein staining in cell bodies and dendrites. This pattern was
seen when using an antibody that specifically detects human but not
mouse a-synuclein (Fig. 6A,D; for negative control, see Fig. 3B). It
was also seen when using an antibody that detects both mouse and
human a-synuclein (Figs. 6B,E, 7B,C) and in sharp contrast to the
axonal and presynaptic distribution of endogenous mouse a-synuclein
in the nervous system of nontransgenic mice (Fig. 6 C, F).
Increased perikaryal and neuritic staining of neurons by
a-synuclein antibodies is one characteristic feature in the diseased
human brain (Spillantini et al., 1997; Wakabayashi et al., 1997;
Baba et al., 1998; Irizarry et al., 1998; Mezey et al., 1998; Spillantini
et al., 1998; Braak et al., 1999). Compared with affected neurons in
human PD brain (Fig. 7A), a-synuclein staining in transgenic
mouse brains showed heterogeneous changes in neurites, very
similar to those observed in human brain (Forno, 1996; Wakaba-
yashi et al., 1997; Spillantini et al., 1997; Baba et al., 1998; Ince et
al., 1998; Irizarry et al., 1998; Mezey et al., 1998; Spillantini et al.,
1998; Takeda et al., 1998; Braak et al., 1999). Frequently observed
changes included sausage-like enlargements of proximal and distal
neuritic segments, thick or fine thread-like inclusions, as well as
Figure 3. Lewy-like pathology in the transgenic mouse spinal cord. A–H
correspond to sections through the anterior horn. A, Prominent perikaryal
and proximal neuritic a-synuclein staining of motor neurons in a transgenic
mouse spinal cord section but not in C57BL/6 (B). C, Campbell–Switzer-
stained motor neurons in a transgenic mouse spinal cord, which also
immunoreacted with anti-ubiquitin antibody (D). E, G, Anti-GFAP and
anti-phosphotyrosine antibody stainings (F, H ) in transgenic (E, F ) versus
nontransgenic (G, H ) C57BL/6 spinal cord show evidence for astrocytic
gliosis (E) and reactive microglia (F) specific to the transgenic tissue. Scale
bars: A–D (in D), 20 mm; E–H (in H ), 20 mm. Magnification: A–D, 2503;
E–H, 2003.
Figure 4. Neuromuscular degeneration. A, Longitudinal section of a spinal
root with human a-synuclein-immunoreactive (LB509 antibody) nerve fi-
bers that are specific to the transgenic mice (C57BL/6 not shown).
B, Holmes–Luxol-stained spinal root showing axonal degeneration with
breakdown and segmentation of myelin into ellipsoids (“digestive cham-
bers”). C, Cross-sectioned bundle of nerve fibers in a muscle showing
strongly human a-synuclein-specific (antibody LB509) immunoreactive ax-
ons. D, Cross-sectioned muscle fiber bundle containing small angular fibers
consistent with denervation (arrowheads), indicating neurogenic muscle
atrophy (Holmes–Luxol stain). Scale bars: A–D, 20 mm. E–J, Medial gas-
trocnemius NMJs from C57BL/6 (E) and two different line 9813 mice
(mouse 1, F–H; mouse 2, I, J ), aged 6.5 months. The combined silver-
esterase reaction reveals nerves in black and the synaptic acetylcholine
esterase reaction product (asterisks) in blue. NMJs in the transgenic mice
show neuropathological changes ranging from swellings of preterminal
nerves (F, arrow), thinning out of the preterminal nerve (G), retraction of the
nerve from the synaptic region (H ), to complete denervation (I, arrows). A
thin and characteristically twisted nerve sprout (arrows) has regrown to a
denervated synapse shown in J. Dark ovals (in I and J ) are attributable to
background labeling of nuclei. Scale bar, 40 mm. Magnification: A, 1003; B,
C, 4003; D, 2003; E–J, 4003.
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beaded or spindle-shaped neurites (Fig. 7B,C). They were most
prominent and frequent in areas including the nucleus centralis
oralis pontis, the nucleus vestibularis lateralis, the deep cerebellar
nuclei, the deep aspects of the tectal plate, and as shown above
(Fig. 3), motor nuclei in the spinal cord.
Immunostaining for ubiquitin is also frequently used to visualize
Lewy pathology in human brain (Gai et al., 1995; Forno, 1996;
Spillantini et al., 1997; Wakabayashi et al., 1997; Baba et al., 1998;
Ince et al., 1998; Irizarry et al., 1998; Mezey et al., 1998; Spillantini
et al., 1998; Takeda et al., 1998; Braak et al., 1999; Go´mez-Tortosa
et al., 2000b). In the transgenic mice, dystrophic neurites and cell
bodies occasionally stained intensely for ubiquitin (Fig. 7E,F). The
stained neurites displayed morphological features (Fig. 7E,F) sim-
ilar to those seen in human brains (Fig. 7D) with Lewy pathology
(Gai et al., 1995; Forno, 1996; Spillantini et al., 1997; Wakabayashi
et al., 1997; Baba et al., 1998; Ince et al., 1998; Irizarry et al., 1998;
Mezey et al., 1998; Spillantini et al., 1998; Takeda et al., 1998;
Braak et al., 1999). However, both neuronal cell bodies and neu-
rites with ubiquitin immunostaining were less frequent when com-
pared with a-synuclein-positive cells and neurites (Fig. 7G,H) and
were restricted primarily to those regions that showed the most
pronounced a-synuclein immunopathology in cells and neurites,
including the nucleus centralis oralis pontis, the nucleus vestibu-
laris lateralis, the deep cerebellar nuclei, the deep aspects of the
tectal plate, and motor nuclei in the spinal cord. Within each of
these regions, neurons and neurites showed no significant ubiquitin
immunostaining, weak staining (with variable degrees of punctate
cytoplasmic and/or perinuclear immunolabeling), or an intense
ubiquitin immunostaining, as illustrated in two consecutive 3 mm
paraffin sections (Fig. 7G,H). These sections show the same set of
cells and neuritic structures in a cerebellar nucleus, stained for
a-synuclein (Fig. 7G) and ubiquitin (Fig. 7H).
Ubiquitin compared with a-synuclein immunopathology in hu-
man brains with Lewy bodies and Lewy neurites is also less
frequent (Forno, 1996; Ince et al., 1998; Irizarry et al., 1998;
Spillantini et al., 1998; Takeda et al., 1998; Braak et al., 1999;
Go´mez-Tortosa et al., 2000b), suggesting that ubiquitination might
be a late event in the development of the pathology in mouse and
human. Curiously, ubiquitination was evident in some but not all of
the mice with a-synuclein immunopathology, and the phenomenon
was observed in both lines (9813 and 9956) and sexes. For example,
in one group of five 6-month-old transgenic mice of line 9813 that
were processed simultaneously for pathology, only two of the five
animals showed a prominent ubiquitin immunopathology in the
restricted brain regions. The stochastic manner in which ubiquiti-
nation appeared led us to compare transgene mRNA levels be-
tween different mice and sexes within each line but no differences
between either individuals or sexes were detected (data not
shown). Apparently, factors other than these or strain genetic
background (all mice are C57BL/6) play a role in this phenomenon.
Finally, ultrastructural features of the human a-synuclein-
positive neuronal inclusions were characterized by immunoelec-
tron and conventional electron microscopy. In contrast to nontrans-
genic C57BL/6 mice, which showed no staining with the LB509
human a-synuclein-specific antibody (data not shown; for refer-
ence, see Fig. 3B), neurons of transgenic mice showed a-synuclein-
containing granular deposits (Fig. 8A,B). Using conventionally
stained ultrathin sections, brainstem and spinal cord tissue of
transgenic but not nontransgenic mice showed dendrites (often
dilated) containing electron-dense finely structured granular mate-
rial (Fig. 8C). a-Synuclein-immunoreactive fibrillar components as
Figure 5. Neurodegeneration of soleus neuromuscular junctions. A–D,
The structure of the postsynaptic apparatus is visualized by a-bungarotoxin
staining of AChRs ( green), which was similar in C57BL/6 (A, C) and
transgenic (B, D) mice. Costainings are shown for a-bungarotoxin ( green)
and synaptophysin (A, B), and a-bungarotoxin and neurofilament (C, D).
Scale bar, 3 mm. Magnification, 7003.
Figure 6. a-Synuclein protein expression in the transgenic mouse brain.
A–F, a-Synuclein staining in the hippocampal CA1 region (A, B) and
neocortex (D, E) of a transgenic mouse compared with the respective
regions in a nontransgenic C57BL/6 mouse (C, F ). Unlike in the transgenic
brain, the C57BL/6 hippocampus lacks a-synuclein immunoreactivity in
CA1 pyramidal cell bodies in stratum pyramidale (st.p.). In both mice,
immunostaining is prominent in stratum radiatum (st.r.). Strongly immu-
noreactive neurites (i.e., CA1 cell dendrites) in stratum radiatum are
specific to the transgenic brain. Similar dendritic structures in the C57BL/6
brain appear pale and without a-synuclein. Immunostaining was in paraffin
(A, D; human a-synuclein-specific antibody LB509) and free-floating brain
sections (B, C, E, F; antibody detects both mouse and human a-synuclein).
Scale bars: A, D (in D), 20 mm (2503 magnification); B, C, E, F (in F ),
20 mm (2003 magnification).
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seen in human brains with Lewy pathology (Spillantini et al., 1997;
Wakabayashi et al., 1997; Goedert et al., 1998; Takeda et al., 1998)
were not seen.
The vast majority of human cases with Lewy pathology are
idiopathic, and a-synuclein mutations in the coding region, other
than A53T and A30P, have not been found in cohorts of familial or
sporadic PD (Chan et al., 1998; Farrer et al., 1998; The French
Parkinson’s Disease Study Group, 1998; Vaughan et al., 1998). To
Figure 7. a-Synuclein and ubiquitin in transgenic mouse and human PD
brain. A–F, Sections are shown of a human PD substantia nigra (A, D) and
a transgenic mouse brain pontine reticular nucleus (B, C, E, F ) immuno-
stained for a-synuclein (A–C) and ubiquitin (D–F). Note the prominent
somatodendritic staining for a-synuclein and the neuritic staining for ubiq-
uitin in both human and mouse neurons. Lewy-like neurites are indicated
by arrowheads. A cell of the substantia nigra in the human PD brain shows
a Lewy body inclusion (A, arrow). G, H, Two consecutive 3 mm paraffin
sections of the same group of cells in a cerebellar nucleus, stained for
a-synuclein (LB509 antibody; G) and ubiquitin (H ). G, Several neurons
showing similar degrees of perikaryal a-synuclein immunoreactivity. Many
cross-sectioned neurites are also stained. H, Abundant ubiquitin immuno-
reactivity is seen in only one of the three grouped cells and a nearby neurite
(arrowheads in H and G indicate the same cell and neurite showing
a-synuclein immunoreactivity). In addition, compared with the number of
a-synuclein-positive neurites in G, in H a smaller number of these struc-
tures (dark and punctate) show immunoreactivity for ubiquitin. Scale bars:
A, D, 20 mm (magnification: A, 3203; D, 6303); B, C, E–H (in H ), 20 mm
(magnification, 4003).
Figure 8. Ultrastructural features of neurons in Thy1aSNA53T mice.
Shown are immunoelectron (A, B) and a conventional micrograph (C) of
spinal cord gray matter. A, B, Five-month-old Thy1aSNA53T mouse of line
9813. The immunoelectron micrographs are specifically stained for human
but not mouse a-synuclein (LB509 antibody). A, Longitudinal section
through a small dendritic appendage showing prominent staining of ele-
ments in the dendritic cytoplasm. B, Immunolabeled cross-sectioned den-
drite, showing the fine granular composition of the a-synuclein-containing
structures, which occasionally appeared attached to the endoplasmic retic-
ulum and mitochondria, for example. C, Conventionally stained electron
micrograph of a brainstem section of a 4-month-old transgenic mouse
showing fine granular electron-dense material in dendritic profiles, most
evident in the cross-sectioned dendrite located in the top right part between
the three larger and a smaller myelinated axon. Scale bars: A, 1.7 mm
(45003 magnification); B, 0.6 mm (12,0003 magnification); C, 1.9 mm
(50003 magnification).
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test whether the pathology seen in the mice is unique for the A53T
mutant of a-synuclein, in which case it could bear little on idio-
pathic forms of the diseases, we also generated transgenic lines
(n 5 5) expressing wild-type human a-synuclein. Wild-type human
a-synuclein (aSNwt) expression was under control of the mouse
Thy1 regulatory sequences as for the A53T mutant (Fig. 1A). Mice
of one of these lines (S969) showed a motor phenotype and
expressed brain transgene mRNA and protein levels similar to
those in seen in Thy1aSNA53T mice of line 9813 (data not shown).
Brain and spinal cord contained many neurons with pronounced
a-synuclein immunostaining in cell perikarya and dendrites (Fig.
9). Cells and neurites with Lewy-like features were prominent and
frequent mainly in those areas of the CNS as reported for the
Thy1aSNA53T mice. Two representative examples shown are from
the deep mesencephalic nucleus (Fig. 9D) and the spinal cord (Fig.
9E,F). Gastrocnemius neuromuscular junctions showed in some
regions over 50% denervation, and sprouting was often seen at the
remaining endplates like in the A53T mice (data not shown). In
conclusion, like its A53T mutant, expression of wild-type human
a-synuclein can cause pathogenicity in central neurons.
DISCUSSION
The transgenic mice described here cover a remarkable spectrum
of the pathological changes that are seen in postmortem brain
tissue of DLB, PD, and LBVAD patients. Our results identify the
A53T mutant of human a-synuclein and its wild-type counterpart
as pathogenic agents that can drive the formation of extranigral
pathology in rodent central neurons. The A53T mutation may
enhance but is not required for pathogenicity of the human protein.
This finding is in agreement with recent reports describing its
pathogenicity in transgenic mice (Masliah et al., 2000) and
Drosophila (Feany and Bender, 2000). Expression of the human
a-synuclein A30P mutant has also revealed changes in neurons that
are reminiscent of Lewy-like pathology in both the mouse (Kahle
et al., 2000a,b) and the fly (Feany and Bender, 2000). Therefore, all
three human a-synuclein proteins can be pathogenic in neurons
in vivo. In each case, their expression resulted in aberrant
perikaryal and dendritic accumulations of a-synuclein in neurons,
suggesting that this could play a central role in the development of
the pathology. In our mice, human a-synuclein expression also
induced motor neuron degeneration, with profound effects on
axonal integrity, and denervation of NMJs in several muscles
examined. These observations suggest that a-synuclein (over)ex-
pression affects a (perhaps universal) mechanism of synapse main-
tenance. Whether the three human a-synuclein proteins affect one
or different (for example, axonal transport; Jenssen et al., 1999)
mechanisms and with similar or different thresholds for pathoge-
nicity remains to be determined. However, because the a-synuclein
gene is infrequently mutated in its coding sequence, it will be key
to identify and study cellular processes that facilitate a-synuclein
protein accumulation, such as after insult (Kowall et al., 2000; Vila
et al., 2000), or its degradation, which likely involves the protea-
some–ubiquitin pathway (Leroy et al., 1998; Bennett et al., 1999).
An interesting feature of the pathology in our transgenic mice
and in human diseases with Lewy pathology (Braak et al., 1996;
Forno, 1996; Ince et al., 1998; Takeda et al., 1998; Braak et al.,
2000) is a selective and topographically confined vulnerability of
neurons to develop Lewy (human) or Lewy-like (mouse) pathol-
ogy. In the mice, prominently affected areas included the nucleus
centralis oralis pontis, the nucleus vestibularis lateralis, the deep
cerebellar nuclei, the deep aspects of the tectal plate, and motor
nuclei in the spinal cord. Of course, the pattern in the mouse is
dictated a priori by the properties of the Thy1 gene-based expres-
sion cassette. This cassette yielded widespread neuronal expression
of a-synuclein. However, pathology was most pronounced in cer-
tain brain regions, suggesting that some neurons are more vulner-
able. Perhaps modulators of a-synucleinopathy vary regionally in
the brain. The Thy1 cassette generally fails to express in dopami-
nergic neurons of the substantia nigra pars compacta (S. Bischoff
and H. van der Putten, unpublished observations), and we con-
firmed this to be the case also in the A53T transgenic mice (data
not shown). In the human brain, the dopaminergic cells of the
substantia nigra pars compacta appear most sensitive to develop
Lewy pathology, and the resulting nigral lesions are primarily
involved in the clinical symptoms of PD (Forno, 1996; Spillantini et
al., 1997; Wakabayashi et al., 1997; Baba et al., 1998; Ince et al.,
1998; Irizarry et al., 1998; Mezey et al., 1998; Spillantini et al., 1998;
Takeda et al., 1998; Braak et al., 1999). Furthermore, when using
transgene cassettes that allow for expression in dopaminergic neu-
rons, these cells seem highly prone to develop Lewy-like pathology
in both mouse (Masliah et al., 2000) and fly (Feany and Bender,
2000). However, extranigral Lewy pathology is very common in
both PD and DLB brains (Gai et al., 1995; Braak et al., 1996, 2000;
Forno, 1996; Go´mez-Tortosa et al., 2000a), and it is suspected to
contribute to the variable cognitive and neuropsychiatric features
in these diseases. By excluding transgene effects in dopaminergic
neurons of the substantia nigra pars compacta, Thy1aSN mice
seem particularly useful to address and model extranigral aspects
of the pathology as it is seen in PD and DLB.
The remarkable spectrum of pathological changes seen in the
mice included subsets of central neurons showing a-synuclein-
stained perikarya, dendrites, Lewy-like neurites, and a smaller
subset of these cells staining for ubiquitin. In contrast, no patho-
logical staining was observed when using antibodies that detect
paired helical filament and hyperphosphorylated tau, neurofila-
ments, or when using stains to detect Ab plaque-like pathology
(Sturchler-Pierrat et al., 1997; data not shown). Ubiquitination was
evident in some but not in all aged-matched female and male mice,
and this phenomenon was observed in both A53T lines. Because all
Figure 9. Immunopathology in Thy1aSNwt. A, Cerebral cortex showing
prominent somatic and axodendritic a-synuclein immunostaining on neu-
rons of the deep cortical layers. B, CA1 region of the hippocampus showing
prominent a-synuclein immunostaining in principal cell somata and den-
drites. C, CA3 sector of the hippocampus. Note some pyramidal cells with
prominent cytoplasmic staining next to unstained cells and the immuno-
staining of the mossy fiber terminals. D, Deep mesencephalic nucleus with
a neuron showing a strong a-synuclein immunostaining in soma and prox-
imal dendrites. Note the presence of unstained axons in the vicinity. E, Spinal
cord longitudinal section with a-synuclein-immunostained motor neurons
and enlarged proximal dendrites (arrow). F, Same area as in E showing
ubiquitin immunostaining in the cytoplasm of some neurons. Scale bars: A, B
(in B), 20 mm; C, D (in D), 20 mm; E, F (in F ), 20 mm. Magnification: A, B,
1003; C, D, 2503; E, F, 3203.
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of the mice were C57BL/6 and no variation in transgene expression
was detected between individuals or sexes within a line, factors
other than these seem to account for ubiquitination occurring in a
stochastic manner.
Like in human PD and DLB brains (Forno, 1996; Ince et al.,
1998; Irizarry et al., 1998; Spillantini et al., 1998; Takeda et al.,
1998; Braak et al., 1999; Go´mez-Tortosa et al., 2000b), ubiquitina-
tion in transgenic mouse neurons appears to be a late modification
in cells with a-synuclein pathology. It was evident in only a subset
of human a-synuclein-immunopositive mouse neurons and neu-
rites (Fig. 7G, H) and found mainly in those brain regions that
showed the most pronounced a-synuclein immunopathology.
A quantification of the number of perikarya and neurites showing
ubiquitin versus a-synuclein immunopathology was not attempted
because, unlike in human brains with Lewy pathology, the pattern
and the intensity of ubiquitin immunolabeling was very heteroge-
neous. In DLB, percentages of a-synuclein-positive but ubiquitin-
negative structures ranged only from 2 to 10% depending on brain
region (Go´mez-Tortosa et al., 2000b). Morphologically, and com-
pared with classical Lewy bodies, these structures corresponded to
less aggregated and less compact a-synuclein inclusions, such as
pale bodies (Dale et al., 1992). a-Synuclein compared with ubiq-
uitin antibodies thus showed higher sensitivity for identifying less
aggregated and less compacted inclusions but little differences with
respect to identifying classical Lewy bodies. In the mice, we have
not seen classical Lewy body-like structures. Perikarya and neurites
contained less compact and more diffuse a-synuclein-immunopositive
material. A significant proportion of a-synuclein-immunopositive
perikarya and neurites failed to show or had different degrees of
punctate ubiquitin staining. Only occasional cells and neurites
showed very intense ubiquitin immunostaining (Fig. 7G, H).
Therefore, compared with human brains with Lewy pathology, the
majority of a-synuclein-positive inclusions in the mice may repre-
sent less compact a-synuclein conglomerates associated with pre-
ubiquitination or early stages of ubiquitination. In human brains,
ubiquitinated structures represent mainly classical Lewy bodies and
Lewy neurites, and punctate ubiquitin immunopathology is less
frequent (Go´mez-Tortosa et al., 2000b). Perhaps aging and/or
species differences account for these observations and also for the
prominent, diffuse, ubiquitin staining seen in the cytoplasm of
occasional mouse but not human neuronal cell bodies (Fig. 6E,F)
in which it is usually confined to Lewy bodies (Gai et al., 1995;
Forno, 1996; Ince et al., 1998; Irizarry et al., 1998; Spillantini et al.,
1998; Takeda et al., 1998; Braak et al., 1999; Go´mez-Tortosa et al.,
2000b). Morphologically, ubiquitin staining of dystrophic neurites
is remarkably similar in both species (Fig. 7D–F, H).
Using transmission and immunoelectron microscopy, human
a-synuclein A53T-immunoreactive granular material was detected
in cytoplasm, dendrites, and occasionally in axons of A53T mice.
Granular material with a-synuclein has been seen in human tissue
with Lewy pathology and in partially purified human Lewy bodies
(Arima et al., 1998; Baba et al., 1998; Goedert et al., 1998; Wak-
abayashi et al., 1998). We did not detect the typical a-synuclein
decorated Lewy body filaments as seen in material extracted from
human DLB cingulate cortex (Spillantini et al., 1998), in tissue
sections from human PD and DLB brain (Arima et al., 1998; Baba
et al., 1998; Wakabayashi et al., 1998), and in synthetic a-synuclein
filaments (Conway et al., 1998; Crowther et al., 1998; El-Agnaf et
al., 1998; Giasson et al., 1999; Narhi et al., 1999; Wood et al., 1999).
This could relate to insufficient aging of the mice and/or species
differences. Others recently reported granular but no fibrillar ma-
terial in mice expressing wild-type human a-synuclein (Masliah et
al., 2000), whereas in Drosophila fibrillar material was seen (Feany
and Bender, 2000). These different findings are intriguing because
the identity of the pathogenic species in diseases with Lewy pa-
thology and its relationship to the a-synuclein-containing fibril has
not been elucidated, and it is not known whether Lewy bodies in
human diseases are cytotoxic, harmless side products, or markers
of cell damage. Irrespective, and likely more important, are the
several other striking similarities seen between the pathology in
human and the transgenic mice. All three (wild-type, A30P, and
A53T) a-synuclein proteins produce nonfibrillar oligomers (Con-
way et al., 2000) that perhaps are critical in pathogenesis, whereas
fibrils and/or Lewy bodies could represent harmless epiphenomena.
In conclusion, the changes in the transgenic mice correlate with
neurodegeneration, confirming that such mouse models provide a
useful means to address fundamental aspects of disorders with
a-synucleinopathy and novel animal models for testing therapeutic
strategies.
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